Abstract:The etiology of Parkinson's disease (PD) has long been thought to involve both genetic and environmental factors. There exists a common theme across the etiological spectrum of PD, where these factors have the ability to cause nigrostriatal dopaminergic (DA) cell death by interfering with mitochondrial function, inducing oxidative stress and altering proteosomal function. The protein α-synuclein (α-syn) that forms characteristic inclusions termed Lewy bodies in familial or sporadic forms of PD is thought to play a central role in PD pathology. Due to the absence of an effective treatment for PD progression, it is necessary to identify various genetic or environmental modifiers to advance drug discovery and therapeutic development. Animal models like Caenorhabditis elegans are often preferable for experimental research in the study of neurodegenerative diseases as this microscopic nematode combines ease of handling and manipulation, high reproductive rates and facilitation of large-scale experiments. Reminiscent of the situation observed in PD patients, expression of PD associated genetic factors or exposure to environmental neurotoxicants causes various phenotypes in worms such as, robust cell-type specific DA neurodegeneration, occurrence of protein misfolding/aggregates and associated behavioral/locomotion defects. These parameters can be analyzed and quantified, thus rendering the nematode model useful for uncovering mechanistic aspects of PD pathology, including genetic or environmental factors, or interactions affecting neurodegeneration. Using C. elegans as an environmental model system, we elucidated the toxicological effects and mechanism for two different classes of bacterial metabolites in causing neurodegeneration/PD related phenotypes. We demonstrated that a previously identified bacterial neurotoxic metabolite produced by Streptomyces spp. caused neuronal cell death as a result of mitochondrial dysfunction and oxidative stress in worms. Interestingly, the neurotoxic effect of this metabolite was enhanced in the presence of α-syn, indicating a functional association. Our study highlights the toxic phenotypes of another group of bacterial products, phenazines, which enhanced α-syn-induced protein aggregation and neurodegeneration in worms. We also determined that phenazine compounds upregulated cellular stress responses in the ER and mitochondria, thus representing a potential PD-related environmental risk factor. Finally, using C. elegans as a genetic model system for PD, we have reported a previously uncharacterized neuroprotective gene product, RTCB-1 that has the ability to regulate xbp-1 mRNA splicing in the unfolded protein response pathway (UPR). Using cell-specific RNA interference (RNAi), we have shown that RTCB-1 rescues α-syninduced DA neurodegeneration by regulating XBP-1 signaling and activating downstream chaperones in the UPR; thus mitigating the toxic effects caused by accumulation of unwanted proteins. The combined outcomes of this research represent mechanistic advances in our understanding of factors, both heritable and environmental, that exert an influence on neurodegeneration. The evolutionarily conserved pathways and functional targets revealed through this work highlight the expeditious manner by which C. elegans can be exploited to accelerate the path toward attenuating devastating diseases like PD. Ms. Arpita Ray University of Alabama Wednesday, May 21, 2014 10:00 AM SEC RM 2436

Use of Caenorhabditis elegans to Unravel the Tripartite Interaction of Kynurenine Pathway, UPRmt and Microbiome in Parkinson's Disease

Gut brain axis: an insight into microbiota role in Parkinson’s disease

Identification and mechanistic analyses of genetic and environmental risk factors associated with Parkinson's disease using a Caenorhabditis elegans model

Multiomics of parkinsonism cynomolgus monkeys highlights significance of metabolites in interaction between host and microbiota

Exploring Caenorhabditis elegans as Parkinson's Disease Model: Neurotoxins and Genetic Implications

Oral, Nasal, and Gut Microbiota in Parkinson's Disease.

Emerging insights between gut microbiome dysbiosis and Parkinson’s disease: Pathogenic and clinical relevance

Multidirectional associations between the gut microbiota and Parkinson's disease, updated information from the perspectives of humoral pathway, cellular immune pathway and neuronal pathway

Regulation of Immune-Driven Pathogenesis in Parkinson’s Disease by Gut Microbiota

Role of gut microbiota in regulating gastrointestinal dysfunction and motor symptoms in a mouse model of Parkinson’s disease

Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease

MPTP Induced Parkinson's Disease in Mouse: Potential Association Between Neurotransmitter Disturbance and Gut Microbiota Dysbiosis.

Using Caenorhabditis elegans to Model Therapeutic Interventions of Neurodegenerative Diseases Targeting Microbe-Host Interactions

Microbiota, Tryptophan and Aryl Hydrocarbon Receptors as the Target Triad in Parkinson's Disease—A Narrative Review

Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease

Gut Microbiota-Induced Modulation of the Central Nervous System Function in Parkinson's Disease Through the Gut-Brain Axis and Short-Chain Fatty Acids

Gut microbiome and Parkinson's disease: Perspective on Pathogenesis and Treatment

Regulation of TIR-1/SARM-1 by miR-71 Protects Dopaminergic Neurons in a C. elegans Model of LRRK2-Induced Parkinson's Disease

The role of gut dysbiosis in Parkinson's disease: mechanistic insights and therapeutic options

The role of the microbiota-gut-brain axis and intestinal microbiome dysregulation in Parkinson's disease

Gut Microbiota Approach—A New Strategy to Treat Parkinson’s Disease